Simvastatin in Patients With Isolated Arterial Hypertension

Simvastatin in the Treatment of Isolated Arterial hyPertension and Prevention of cARdiovascular Events

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01017835

Acronym

STIPPARE

Enrollment

Registered

2009-11-23

Start date

2009-11-30

Completion date

2012-01-31

Last updated

2009-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

statins, isolated hypertension, atherosclerosis, lipid profile

Brief summary

The purpose of this study is to determine whether combined therapy with simvastatin and hypotensive drugs (ACEI or ARB) may decrease the blood pressure. Moreover, we would like to assess the influence of isolated hypertension on endothelial injury, and on the development of atherosclerosis.

Detailed description

Hypertension is one of the most important predictors of cardiovascular diseases (CVD). Due to the fact that hypertension frequently coexists with hypercholesterolemia and diabetes which increase the risk of CVDs development, it is advisable to use the optimal combined therapy (hypotensive + hypolipidemic + hypoglycemic)in this group of patients. Statins are the most effective and widely used drugs for the treatment of hypercholesterolemia. According to the available experimental and clinical data they may decrease the blood pressure (BP) in normotensive and hypertensive patients. However, it is still difficult to determine to what degree the reduction of both blood pressure and cardiovascular risk is due to hypotensive or hypolipidemic/pleiotropic effects of statins.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* isolated hypertension (I or II class according to ESH guidelines 2009)

Exclusion criteria

* ischemic heart disease, prior percutaneous coronary intervention (PCI), prior coronary artery bypass grafting (CABG), heart failure, diabetes, hyperlipidemia, active smokers

Countries

Poland

Contacts

Primary ContactMarta Michalska, MSc

michalska_marta84@wp.pl501154853

Backup ContactMaciej Banach, MD PhD

maciejbanach@aol.co.uk604593040

Outcome results